Abstract. Posttranslational modification by covalent attachment of polyisoprene intermediates to a carboxyterminal CAAX-box motif is required for the biologic function of proteins such as p21-, the supergene family of ras-related proteins, nuclear lamins, and subunits of heterotrimeric G-proteins. Cells grown in the presence of lovastatin, which inhibits HMG-CoA reductase and prevents synthesis of intermediates required for protein prenylation, develop a round, refractile morphology. Our data indicate that this is due to the selective loss of actin cables without gross changes in the microtubular lattice or intermediate filament structure. Microinjection of a competitive peptide inhibitor of protein prenyltransferases into the cytoplasm of cells induces an identical change in morphology with loss of actin cables . Mevalonate (MVA) reverses the lovastatin-induced morphologic change by inducing a rapid repolymerization of actin cables with coincident rever-SCENT findings have provided insights into new physiologic roles for intermediates in the cholesterol biosynthesis pathway ) . Mevalonate (MVA)' is the precursor of two isoprenoid intermediates, famesyl-pyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), that are substrates for posttranslational modifications in which the lipid moiety is covalently transferred to a diverse group of cellular proteins (Schmidt et al ., 1984) . Farnesylated proteins include the nuclear envelope protein lamin B (Farnsworth et al., 1989) , the gamma subunit of bovine transducin (Fukada et al., 1990) , and ras proteins Schafer et al., 1989; and Casey et al., 1989). Data indicate thatmore cellular proteins are modified by geranylgeranyl than by farnesyl moieties Epstein et al., 1990) . These include the gamma subunits of heterotrimeric G-proteins (Yamane et al., 1990; Mumby et al., 1990) , and members of the ras-related family of low molecular weight GTP-bind- sion to the flat morphology. Furthermore, microinjection of farnesyl-pyrophosphate or geranylgeranyl-pyrophosphate into lovastatin-treated cells also results in rapid morphologic reversion . The morphologic reversion induced by MVA requires the presence of serum, and is independent of extracellular calcium . The addition of cycloheximide to the growth medium prevents lovastatin-induced loss of actin cables, and causes morphologic reversion of lovastatin-treated cells by a mechanism that is independent of MVA . AlF4_ induces morphologic reversion in a manner indistinguishable from MW These data indicate that prenylated protein(s) play a critical role in regulating the state of intracellular actin, and that GGPP can rescue the lovastatin-induced morphologic phenotype in the absence of upstream intermediates of cholesterol biosynthesis. We have begun to dissect the signaling events that mediate this pathway.
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ing proteins, such as G25K (Yamane et al., 1991) , the rac 1, rac 2, and ral A proteins (Kinsella et al ., 1991) , rap1B (Kawata et al., 1990) , rab proteins (Khosravi-Far et al., 1991; Farnsworth et al., 1991; Kinsella and Maltese, 1991) , and rho A (Yoshida et al., 1991) . Carboxy-terminal lipids form part ofthe hydrophobic signal that targets proteins to various membranes within the cell where a diverse group of functions are performed (Maltese and Sheridan, 1987) . These include forming part of the nuclear envelope (lamins; Wolda and Glomset, 1988) , playing a crucial role in intracellular trafficking such as occurs with secretory vesicles (ras-related proteins; Bourne et al., 1990) , and the control ofcell growth and division (ras proteins; Hancock et al.,, 1989; Schafer et al ., 1989 ; Casey et al ., 1989) .
Two distinct prenyl-transferases have been identified which utilize FPP or GGPP as substrates for the covalent modification of conserved carboxy-terminal CAAX-motifs (a cysteine residue followed by two aliphatic amino acids and any amino acid) . The cysteine residue is enzymatically linked to the lipid via a thioether bond, followed by proteolytic cleavage ofthe three terminal amino acids, and in some cases carboxyl methylation of the terminal cysteine residue (Clarke et el., 1988; Gutierrez et al., 1989) . Genetic and biochemical evidence indicates that famesyltransferase (FT) and geranylgeranyltransferase (GGT) share a common alpha subunit but have distinct ß-subunits which account for their distinct substrate specificities (Chen et al., 1991) . GGT preferentially utilizes leucine or phenylalanine in the X position, while FT recognizes a broader spectrum ofamino acids and often utilizes methionine or serine in the X position (Reiss et al ., 1991; Yokomama et al., 1991) . Thus, while the specificity for protein prenylation appears to reside in the CAAXbox sequence, the functional significance ofthedifferent lipid modifications remains to be determined.
The discovery that many cellular proteins require prenylation for biologic function, and that these proteins play key regulatory roles within the cell, has stimulated experimentation to identify other cellular processes that are regulated by prenylation . For more than a decade, it has been known that inhibition of HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, leads to arrest of cell growth and a concomitant change in morphology in which adherent cells become round and refractile (Schmidt et al., 1982; Goldstein and Brown, 1990) . The metabolic effects of lovastatin are prevented by addition of MVA (the product of the HMG-CoA reductase reaction) to the culture medium, but not by exogenous cholesterol, a major end product of this metabolic pathway.
In the present study we examine the relationship between the cholesterol biosynthesis pathway and its effects on cellular growth and morphology. We have investigated the molecular basis for the lovastatin-induced morphologic change, and found that actin cables are reversibly depolymerized when cells are treated with HMG-CoA reductase inhibitors; other cytoskeletal structures such as intermediate and thick filaments do not appear to be affected . This effect is reversed within minutes by the addition of MVA to the growth medium or the intracellular injection of MVA, FPP, or GGPP The data indicate that at least one prenylated protein plays a major role in a pathway governing the equilibrium between filamentous and globular actin. 
Materials and Methods

Cell Culture
Cells were maintained at 37°C in a humidified incubator with 5 % COZ and grown in DMEM supplemented with 10% FCS and penicillin and streptomycin . The Kl cell line was derived from a human renal cell carcinoma after collagenase and DNAse treatment of the primary tumor. This line has grown continuously in culture for nearly one year, has a very slow growth rate, and is contact inhibited upon reaching confluence .
Preparation of the Open Acid Form ofLovastatin 1 g of lovastatin was dissolved in 25 ml of 100% ethanol . 37.5 ml of 0.1 N The Journal of Cell Biology, Volume 117, 1992 sodium hydroxide was added and the solution was heated for 2 h at 50°C. The solution was rapidly cooled to room temperature on ice, and the pH was adjusted to 7.2 with hydrochloric acid . The volume was brought to 250 ml with sterile water, and the resulting 10 mM solution was aliquoted, and stored at -20°C.
Antibodies
A murine IgGI mAb directed against ß-tubulin was purchased from Sigma Chemical Co . and used at a dilution of 1 :200. A murine IgG2a mAb antibody directed against vimentin was obtained from Boehringer Mannheim Biochemicals (Indianapolis, IN) and diluted 1 :5 before use . Cytokeratin was stained with undiluted murine mAb (tissue reagent) from Becton Dickinson (Mountain View, CA) . Fluorescein-labeled goat anti-mouse IgG (F[aV]Z specific fragment) was obtained from Organon Teknika Corporation (West Chester, PA) and used at a dilution of 1 :50. The neutralizing mAb Y13-259, directed against p21" proteins, was purchased from Oncogene Science (Manhasset, NY) .
Fluorescence Microscopy
Cells grown on glass coverslips were fixed and stained at various times after culture in lovastatin or the addition of MVA to the culture medium (morphologic reversion experiments) . For staining with fluorescent phalloidin, cells were washed twice with PBS and fixed in 3.75 % formaldehyde/PBS for 10 min at room temperature . Coverslips were washed twice in PBS, extracted with acetone at -20°C for 3 min, air dried, and stored at -20°C or stained immediately. 10 pl of FITC-phalloidin (equal to one unit) was dried under vacuum, redissolved in 200141 of PBS, and 100-20014 were applied to each coverslip. Coverslips were incubated in a humidified chamber for 20 min at room temperature, washed twice in PBS, and mounted with cell side down in a 1 :1 solution of PBS/glycerol, and the edges sealed with nail polish . Stained cells were stored in the dark at 4°C . For antibody studies, cells were fixed in acetone/methanol 1 :1 at -20°C for 10 min . Cells were washed twice in PBS and immediately stained with the primary antibody in a humidified chamber at room temperature. After 30 min, coverslips were washed twice in PBS and stained with fluorescein-conjugated second antibody for 30 min . The cells were washed twice with PBS and mounted as described above . Cells were viewed with an Olympus microscope through a 50x or 100x oil immersion lens, and photographed using an Olympus Exposure Control Unit and Ektar 1000 film .
Quantitation of Cell Morphology
In many experiments, the percent of morphologically flat cells as compared with round, refractile cells was quantitatively determined . This was done by photomicroscopy of cell cultures (Nikon inverted microscope with a 10 x phase contrast lens) at the indicated times after changes in cell culture conditions . Cells contained within two randomly chosen 2 x 3-cm areas of each photograph were counted (50-100 cells per field) and expressed as the percent of the total number of cells which exhibited a flat morphology. The round, refractile morphology induced by lovastatin was easily distinguished from cells with a flat morphology, especially with cell lines KI and NIH 3T3 whose normal morphology is extremely flat .
Microinjection Assay
For peptide injections, cell lines were seeded onto etched glass coverslips and cultured in 35-mm dishes with DMEM/10 % FCS for -24 h before injection of coded peptide samples (Smith et al ., 1990) . After injection, cultures were maintained in growth medium for an additional 18-24 h at which time they were scored for morphologic change and stained with FITCphylloidin for analysis of actin cables . The peptide TKCVIM corresponds to the carboxy-terminal six amino acids of the human p21K-`WB protein and contains a CAAX-box sequence (CVIM), while the control TKVCIM does not (Reiss et al ., 1990) . These peptides were dissolved in 10 mM DTT, 5 % DMSO at a final concentration of 2 .5 mg/ml . Injected cells received -10 -11 ml. Stock solutions of MVA, FPP, and GGPP were diluted with PBS to the stated concentrations before injection into lovastatin-treated cells . FPP and GGPP form micelles in aqueous solutions ; this causes clogging of the microinjection needle thus limiting the concentration at which injections can be made and making estimation of the amount of the compounds injected difficult . Microinjection of ras-specific antibody Y13-259 has been described previously (Smith et al ., 1986) .
Results
Molecular Basis of the Lovastatin-induced Morphologic Change
The molecular basis by which lovastatin and other HMGCoA reductase inhibitors induce adherent cells to alter their morphology to a round, refractile state has not been elucidated. To investigate the mechanism for this morphologic change, the effects of lovastatin on the cytoskeletal architecture of cell line Kl were analyzed . KI was derived from a human renal cell carcinoma, has been continuously passaged under standard cell culture conditions (DMEM/10% FCS), and grows with an extremely flat morphology such that relevant cytoskeletal structures are well demonstrated by fluorescence microscopy. However, the results described for line Kl are similar for other cell lines, including NIH 3T3, which has also been studied extensively.
Kl cells were grown in the presence or absence of lovastatin and cells were fixed and stained with FITC-phalloidin, which specifically stains filamentous-actin (as in actin cables), but not actin monomers. As shown in Fig. 1 a, KI cells grown under normal conditions contain numerous actin cables which traverse the cell and extend to the plasma membrane . In contrast, Kl cells grown in 30 AM lovastatin for 20 h are round and refractile, and no actin cables are seen (Fig. 1 b) . The diffuse and occasional punctate staining of rounded cells by FITC-phalloidin suggests that oligomers of actin persist in these cells although they are not discernible as discrete structures by light microscopy. To determine whether this effect of lovastatin on actin cables could be reversed by MVA, medium was removed from identical culture plates as shown in Fig . 1 b and replaced with medium containing 30 AM lovastatin plus 1 mM MVA . Morphologic reversion to a flat phenotype occurred very rapidly; 15 min after MVA addition, most cells had regained a flat morphology. Accompanying this morphologic reversion was the reappearance of actin cables, although these were initially very short and thin, and appeared primarily to be located peripherally, near the plasma membrane ( Fig. 1 c) ; few cables traverse the entire cell . After 30 min, numerous actin cables were apparent which extend the full length of the cell ( Fig. 1 d) ; these are still thin and wispy as compared to untreated cells, suggesting that cross-bundling ofnewly formed cables by actin-associated proteins is a later event . Within a few hours, actin cables became indistinguishable from those in Fig. 1 a (not shown) and the reverted KI cells proliferated in media containing MVA and lovastatin until confluence was attained.
When K1 cells were stained with antibodies specific for ß-tubulin or vimentin, a different pattern emerged . As shown in Fig . 2 a, Kl cells stained with an antibody specific for tubulin possess an extensive microtubular network . Following growth for 20 h in 30 AM lovastatin, the cells undergo the expected morphologic change ; however, the microtubular array remains intact with no evidence of disassembly (Fig. 2 b ; viewed at high power) . After 15 min of growth in MVA, the microtubular lattice is again noted to be a polymerized network, even in cells in an early stage of reversion (Fig. 2, c and d) . Similarly, KI cells stained with antibodies directed against vimentin or cytokeratin demonstrate the characteristic peri-nuclear meshwork with cytoplasmic extension, and lovastatin-treated cells show no evidence ofdisFenton et al . The Mevalonate Pathway Affects Actin Polymerization solution of these intermediate filament complexes (data not shown) . Thus, the loss ofactin filaments in lovastatin treated cells does not represent a general effect on all cytoskeletal components.
Morphologic Change Induced by Inhibition ofPrenyl-transferases
Todetermine whether lovastatin induces morphologic change via inhibition of protein prenylation, K1, NIH 3T3, and Rat 1 cells were microinjected with synthetic peptides, one of which is a potent competitive inhibitor of FT, and likely an inhibitor of GGT as well at the high concentrations microinjected. When these cell lines were microinjected with the inhibitor peptide TKCVIM, 25-35% of the cells in the injected field had become refractile with loss of actin cables within 20 h (Fig. 3 b, and Table I ) . As a control, the peptide TKVCIM was microinjected . This hexamer is not a substrate for either prenyltransferase, due to the position of the cysteine residue (yet it has the same overall amino acid composition as the inhibitory peptide) . In this case, no morphologic change distinct from background was noted, andactin cables were maintained (Fig. 3 a; Table I ). From these data we conclude that inhibition of prenylation of one or more CAAXcontaining proteins results in a morphologic phenotype indistinguishable from that caused by lovastatin and is likely the result of inhibition of the same metabolic pathway.
Microinjection ofFPP or GGPPInduces Morphologic Reversion
The previous data suggested that prenylated cellular proteins were required for maintenance ofactin cables . To further establish this point, lovastatin-treated cells were microinjected with MVA, FPP, or GGPP . As shown in Table II , injection of each of these compounds leads to morphologic reversion of the majority of injected cells. No obvious differences in the kinetics of reversion were noted with the three compounds, as reversion was rapid in all cases . These data indicate that GGPP can induce morphologic reversion in the absence of other prenyl intermediates such as FPP, suggesting that proteins that can be modified by geranylgeranyl rather than farnesyl are responsible for inducing morphologic reversion . Reversion induced by MVA and FPP may result from their in vivo conversion to GGPP Other data independently support the concept that ras proteins are not required for morphologic reversion. When lovastatin-treated Kl cells are coinjected with the ras-specific antibody Y13-259 and MVA, rapid morphologic reversion ensues (Table II) . Identical results are observed when Y13-259 is microinjected 1 h before addition of MVA to the culture medium (data not shown) . The neutralizing activity of Y13-259 is maintained in Kl cells, since injection of this antibody into serumstarved KI cells blocks serum induction of DNA synthesis .
Requirementsfor Serum and Extracellular Calcium
To determine whether the presence of serum in the culture medium was required for MVA-induced reversion, complete media was removed from lovastatin-treated cells and replaced with DMEM lacking serum but containing 1 mM MVA and 30 AM lovastatin. As shown in Table III , serum was required for the initial rapid phase of reversion (note the lack of reversion at 30 min), but by 60 min the cells were Table I . Bar, 10 j,m .
beginning to flatten, and by 2 h after treatment, nearly control percentages of flat cells were observed .
Intracellular free calcium is an important second messenger for many stimulus-response processes in eukaryotic cells . To determine whether MVA might act by inducing a rapid influx of extracellular calcium into the cell, lovastatintreated Kl cells were cultured in calcium-free DMEM containing 10% FCS, 30 p,M lovastatin, 1 mM MVA, and 1 or 2 mM EGTA . Treatment under these conditions had no effect on the MVA-induced morphologic reversion (Table III) . These data suggest that extracellular calcium is not required (TKCVIM) , and cultured for an additional 20 h in DMEM/10% FCS . Cells within the injected area were then scored for "% of cells with a refractile morphology ." The standard deviation from four separate experiments is given in parentheses .
The Journal of Cell Biology, Volume 117, 1992 for MVA-induced morphologic reversion . Also, extracellular calcium is not required for the kinetically slower reversion induced by cycloheximide (see next section) .
Morphologic Reversion Can Be Independent of MVA
The rapid repolymerization of actin cables after rescue with MVA made it unlikely that de novo synthesis of new actin Table II monomers was induced by MVA. To formally exclude this possibility, experiments were performed in which CHA was added to cells treated with lovastatin. Lovastatin and CHA were simultaneously added to preconfluent cultures of K1 cells and morphology assessed after 20 h. As seen in Fig.  4 b, cells treated with lovastatin alone undergo the expected morphologic change, whereas those treated with lovastatin plus 5 /,g/ml CHA are protected from the lovastatin effects and retain a flat morphology (Fig. 4 , compare a, b, and c).
Staining of lovastatin/CHA-treated cells with FITC-phalloidin revealed abundant actin cables (data not shown) . CHA was effective at doses from 2.5 to 10 ug/ml . Cells cultured in CHA plus lovastatin retain the flat morphology for -24 h, then begin to die presumably due to the toxic effects of prolonged inhibition of protein synthesis. Actinomycin D treatment ofKI cells (1, 10, or 50lAg/ml) blocked the morphologic changes in a similar manner, although these results were complicated by cytotoxic effects seen 15 h after actinomycin D treatment ofK1 cells . CHA and actinomycin D had similar effects on lovastatin-treated NIH 3T3 cells. These data suggested that a labile protein was required for lovastatin to mediate its effects on cell morphology. If this were true, CHA might induce reversion of refractile, lovastatin-treated cells, independently of MVA. To test this hypothesis, KI cells were incubated in 30 wM lovastatin for 20 h, at which time CHA was added to the growth media. As shown in Fig . 4 , the initially highly refractile population (Fig. 4 b) was induced to revert to a flat morphology over the ensuing 7 h (Fig. 4, df) . When quantitated the data are as follows: before the addition ofCHA, 92 % ofKl cells were refractile (only 8 % flat) . 1 h after CHA addition, 30% of cells were flat, and after 2.5 and 7 h, 57 and 95 % of cells had attained a flat morphology, respectively. The kinetics of CHA-induced reversion are significantly slower than that observed with MVA, and could reflect the halflife of a labile protein that is required to maintain actin cables in the depolymerized state .
AIF4-has been shown to activate trimeric G-proteins by causing protein-bound GDP to mimic GTP (Bigay et al., 1987) , which can result in the generation of G-protein mediated secondary signals . AIF4 induces a rapid MVA-indepenFenton et al . The Mevalonate Pathway Affects Actin Polymerization dent morphologic reversion of lovastatin-treated K1 cells such that by 30 min after its addition 85 % of Kl cells attain a flatmorphology (Table IV) . When stained with FITC-phalloidin, the reverted cellshadrepolymerized theiractincables, and appeared indistinguishable from those reverted with MVA (data not shown) . Unlike the kinetically slow CHAinduced reversion, the kinetics of AIF4--induced reversion are rapid, and closely parallel the effect ofMVA. NaF alone has a partial effect (as has been observed in other systems), whichmay be due to the ubiquitous contamination oflaboratory water and glassware with low levels ofaluminum (Sternweis and Gilman, 1982; O'Shea et al ., 1987; Donaldson et al., 1991) . However, the specific mechanism of action of AIF4 in our system is speculative, and could reflect other pharmacologic activities such as phosphatase inhibition by the fluoride ion .
Discussion
The molecular basis for the morphologic effects induced by lovastatin on cultured cells was investigated . Inhibition of MVA synthesis (by lovastatin) and the concomitant inhibition of protein prenylation (also demonstrated by injection of CAAX-box encoding peptides) is accompanied by loss of actin cables as assessed by light microscopy. The physical state of actin in these cells is unknown ; however, since the refractile cells are diffusely stained by FITC-phylloidin (which does not stain actin monomers), it seems likely that actin exists as short oligomers that retain the capacity to bind phylloidin. This raises the important issue of the role of actin-binding proteins in these events, as it seems very likely that the physiologic activities of such proteins, i.e., severing and capping of filaments, or binding to actin monomers, will be important in the processes described here. Interestingly, during morphologic reversion after MVA addition, the earliest discernible actincables are observed at the cell periphery, near the cell plasma membrane (Fig. 1 c) . This is consistent with electron microscopic data that identified gelsolin bound to short actin oligomers near cell membranes and suggests that gelsolin-capped actin oligomers may nucleate actin polymerization at the cell periphery (Hartwig et al., 1989) . While lovastatin treatment has dramatic effects on microfilaments, it appears that other constituents of the cell cytoskeleton such as the microtubular lattice and intermediate filaments composed of cytokeratin or vimentin are not grossly affected (although subtle alterations of these structures are not excluded) .
Injection of a peptide inhibitor of famesyl-transferase leads to a change in morphology and loss of actin cables indistinguishable from that observed with lovastatin treatment. Recently, the substrate preferences of FT and GGT have been analyzed utilizing synthetic peptides or cloned protein substrates as prenyl-acceptors (Reiss et al., 1991; Yokoyama et al., 1991) . FT prefers serine or methionine in the X-position, and binding is reduced -10-fold when aliphatic amino acids occupy this position. GGT utilizes leucine or phenylalanine preferentially. It appears that half-maximal activities for both transferases is below 10 uM and that in vitro enzyme specificity is lost when peptide concentrations approach 50 ,.M (Yokoyama et al ., 1991) . In our experiments, the intracellular concentration of injected peptides approaches 50 j,M, and thus the distinction cannot be made between inhibi- (final concentrations of 25 mM and 50 AM, respectively) was added to the culture medium . At the indicated times following these additions, the "% cells exhibiting a flat morphology" was determined .
* At 2 h, AIF4 -became toxic to KI cells .
tion ofFT or GGT. However, the lack of effect of the control peptide indicates that inhibition ofprotein prenylation is the mechanism of action. The mechanism of lovastatin's effect upon cellular architecture thus appears to be a depletion of the prenyl-pyrophosphate substrate(s) required for the prenyltransferase reaction(s) .
To further analyze the role ofprenyltransferases in regulating the actin equilibrium, MVA, FPP, or GGPP was injected into lovastatin-treated cells ; in each case rapid morphologic reversion ensued. Since the injection ofGGPP does not provide upstream intermediates such as FPP, it appears that the GGT reaction is critical in repolymerization of actin. This suggests further that famesylated proteins (such as ras) are not required for these events. The latter point is supported by the failure ofinjected Y13-259 antibody to prevent MVA-induced morphologic reversion . One caveat is that at high concentrations ofGGPP, either FT or GGT may become promiscuous with respect to prenyl-substrate or protein acceptor and utilize GGPP to modify proteins that would be famesylated under physiologic conditions . Nevertheless, our data suggest that one or more geranylgeranyl-modified protein regulates actin polymerization . Data from others demonstrates that growth of Vero cells in the presence of Clostridium botulinum exoenzyme C3, which ADP-ribosylates rho and rac family members (but perhaps other cellular proteins as well), results in an altered cell morphology with loss of actin cables (Chardin et al., 1989) . Both rho and rac proteins are known to be modified by carboxy-terminal geranylgeranyl (Yoshida et al ., 1991; Kinsella et al., 1991x) . It remains to be determined whether these distinct experimental approaches are studying manifestations ofthe same biochemical pathway.
When Kl cells were grown in calcium (-) DMEM containing EGTA, the rapid MVA-induced reversion was unaffected . Thus extracellular calcium is not required for actin repolymerization induced by this pathway ; the possible role of intracellular stores of calcium in these events is not yet known. This point is relevant, since some severing and capping proteins such as gelsolin, are activated by micromolar concentrations ofcalcium (Yin and Stossel, 1980) , resulting in the net shortening of actin cables .
Surprisingly, lovastatin's morphologic effects are prevented by coincubation of cells with CHA . The addition of CHA to cells previously rendered refractile by lovastatin treatment leads tomorphologic reversion which is independent ofexogFenton et al . The Mevalonate Pathway Affects Actin Polymerization enous MVA. The time course ofthis CHA-induced reversion is much slower than that induced by MVA, with the initial reversion noted 1-2 h after CHA addition . These data are consistent with the existence ofa labile cellularprotein which plays a critical role in regulating the polymerization state of intracellular actin. The identity and physiologic function of this protein is not known; it could play a regulatory role (i.e., as a protein kinase or phosphatase) or directly interact with actin filaments or monomers.
AIF4-, which is thought to activate heterotrimeric G-proteins and thus induce second messenger formation, also induced MVA-independent reversion . The kinetics were similar to those of MVA, consistent with a rapid activation of signaling events required for actin polymerization . Since AIF4-induces morphologic reversion even in the continued presence of lovastatin, the AlF4 activation event must be distal to the prenylated protein(s) in this regulatory pathway. This hypothesis presumes that AIF4-activates only trimeric G-proteins, and not other GTP-binding proteins such as members of the ras supergene family. Recently, it was demonstrated that AIF4-does not inhibit GDP release from small GTP binding proteins including ras, rap, rabl, rab3, and ADP ribosylation factor, suggesting it does not activate these proteins (Kahn, 1991) . The ability of the combination of NaF and AIC13 to induce morphologic reversion of lovastatin-treated cells does not prove that the biologic effect is mediated by trimeric G-proteins . Other mechanisms such as inhibition of protein phosphatase activity are possible. Nevertheless, AIF4-does provide a useful pharmacologic reagent with which to study interactions between the mevalonate pathway and the cytoskeleton .
The datapresented are consistent with the following model of lovastatin's effects on actin physiology. Under normal growth conditions, one or more prenylated proteins are required to maintain actin in the polymerized state. It promotes polymerization by inhibiting a labile "protein X," whose normal activity either directly or indirectly results in the depolymerization and/or severing ofactin cables. In cells grown in medium containing lovastatin, the prenylated protein(s) degrades, and no active species can be synthesized in the absence of isoprenoid intermediates . This results in the removal ofthe inhibitory signal on "protein X" with resultant depolymerization of actin cables and morphologic alteration. In culture medium containing CHA and lovastatin, "protein X" also degrades and the lovastatin effect cannot be manifested. Therefore actin cables are "rescued" from the lovastatin effect by CHA.
The MVA-induced morphologic reversion of lovastatintreated cells can be explained in the following manner. Upon addition of MVA (or microinjection of FPP or GGPP), the expanded pool of precursor proteins is activated by prenylation and other carboxy-terminal processing events. One or more prenylated protein(s) initiates a signaling cascade that may include a trimeric G-protein (AIF4 activated), leading to inactivation of "protein X" and subsequent morphologic reversion. When CHA is added to lovastatin-treated cells, "protein X" levels decline, and the block to actin polymerization is removed . Since "protein X" acts distal to the prenylated regulatory protein, these events are independent of MVA. The kinetics of this reversion are determined by the degradation t,rz of "protein X, and hence the kinetics are considerably slower than reversion mediated by MVA, whose time ND course is determined by rapid posttranslational and intracellular signaling events. This model is useful in that it makes a number ofbiochemical predictions that can be tested in the laboratory.
